Price T Rowe Associates Inc Immuneering Corp Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Immuneering Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 859,374 shares of IMRX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
859,374
Previous 910,266
5.59%
Holding current value
$1.6 Million
Previous $2.63 Million
58.21%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding IMRX
# of Institutions
55Shares Held
9.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$3.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$1.99 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$1.77 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.38 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX550KShares$1.02 Million0.22% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $49.1M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...